BRIEF-Puma Biotech applies for marketing approval for breast cancer drug

* Submits NDA for PB272 (neratinib) to U.S. FDA for extended

adjuvant treatment of HER2-positive early stage breast cancer

Source text for Eikon:

Further company coverage:

Read more